Pacific Shuanglin Bio-pharmacy Hits Day Low Amid Price Pressure at CNY 12.39

Pacific Shuanglin Bio-pharmacy Co., Ltd. experienced a notable decline of 3.95% on June 1, 2026, reaching an intraday low of CNY 12.39. This performance stands in contrast to the China Shanghai Composite, which saw a modest decrease of 0.27% on the same day. Over the past week, Pacific Shuanglin has shown a slight recovery with a 1.89% increase, but its longer-term performance remains concerning, with a staggering 44.01% drop over the past year. The company's financial metrics reveal significant challenges, including a net sales decline of 8.47% and negative results reported for six consecutive quarters. Operating cash flow has reached a low of CNY -201.95 million, and the return on capital employed (ROCE) is at a minimal 4.38%. Despite a market capitalization of CNY 10,536 million and a dividend yield of 2.12%, the stock has underperformed the broader market significantly over various time frames, including a 64.76% decline over the past five years. These factors contribute to a challenging outlook for Pacific Shuanglin in the competitive pharmaceuticals and biotechnology sector.